Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors
Completed · Phase 1
Conditions studied: Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
In brief
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have primary or metastatic melanoma or brain tumors.
Key facts
- Study ID
- NCT00002754
- Run by
- Duke University
- People needed
- 6
- Starts
- 1993-02-01
- Expected to finish
- 2001-04-01
- Last updated by the study team
- 2013-02-20
Who can join
Age: 3 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.